Zynerba Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$34,820,072 over the previous period. Total operating expenses were $35,251,540.
Profit Margin
| 2014 | 810.01K | -5.66M | -699.94% |
|---|---|---|---|
| 2015 | 278.9K | -12.55M | -4500.3% |
| 2016 | 7.25K | -23.38M | -322600.1% |
| 2017 | 7.25K | -32.01M | -441549.02% |
| 2018 | 86K | -39.91M | -46408.34% |
| 2019 | 0 | -31.43M | |
| 2020 | 0 | -50.40M | |
| 2021 | 0 | -37.60M | |
| 2022 | 0 | -34.82M |
0M40.L Income Statement (2014 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||
Revenue | 0 | 0 | 0 | 0 | 86K | 7.25K | 7.25K | 278.9K | 810.01K |
Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross profit | 0 | 0 | 0 | 0 | 86K | 7.25K | 7.25K | 278.9K | 810.01K |
Operating exp. | |||||||||
Research and development | 21.09M | 21.42M | 35.65M | 20.38M | 27.24M | 22.80M | 16.78M | 7.44M | 2.40M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 35.25M | 36.77M | 52.06M | 34.31M | 40.48M | 32.82M | 23.21M | 12.81M | 6.47M |
Operating income | -35.25M | -36.77M | -52.06M | -34.31M | -40.39M | -32.82M | -23.20M | -12.53M | -5.66M |
Other income (expenses), net | 215.73K | -538.63K | 725.71K | 1.37M | -474.66K | 810.70K | -288.64K | 7.35K | -1.84K |
Income before tax | -35.03M | -37.30M | -51.33M | -32.94M | -39.91M | -32.01M | -23.41M | -12.52M | -5.66M |
Income tax expense | -215.73K | 291.49K | -932.74K | -1.51M | 486.65K | -27.54K | -27.54K | 27.54K | 0 |
Net income | -34.82M | -37.60M | -50.40M | -31.43M | -39.91M | -32.01M | -23.38M | -12.55M | -5.66M |
Earnings per share | |||||||||
Basic EPS | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 |
Diluted EPS | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |